DEA allows anti-legalization pharma corporation to produce synthetic THC

chemicals that mimic the effects of tetrahydrocannabinol (THC).

But mimicking the effects does not mean that it will lead to same results as marijuana. Research on the drug suggests that spice and other forms of synthetic cannabis are capable of producing more intense and prolonged effects at much lower doses than organic cannabis because they affect more of the body and mind.

Announcing that their product is on the market, Insys detailed the treatment possibilities for cancer, AIDS, and other diseases.

Representatives of the company also stated that “Syndros may cause psychiatric and cognitive effects and impair mental and/or physical abilities.”